Adimab LLC. Provides Update On Recent Partnerships And Milestones

-Announces New Partners and Expansion of Existing Partnerships-

- Achieves Milestones with Multiple Partners, including Arsanis Dosing First Patient-

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with several new companies, as well as expanded partnerships with several of its current partners. In addition, Adimab announced the achievement of technical and development milestones under a number of existing agreements.

“Most of Adimab’s existing partners have sought to expand their relationships beyond the initial terms of the engagement; recently expanded partnerships include those with Five Prime, Innovent Biologics, Acceleron, Potenza, Jounce Therapeutics, Surface Oncology, and Alector.”

In less than seven years, Adimab has entered into over 35 partnerships focused on the discovery of therapeutic IgGs and bispecific antibodies. Adimab’s partnering strategy initially focused on large pharmaceutical companies. However, more recently the company has been able to craft deal structures to accommodate the strategic needs of many innovative early-stage companies backed by leading venture firms like Third Rock Ventures, Atlas Ventures, MPM, Polaris Partners and Orbimed Advisors. Recent new partners include Fortress Biotech, Torque Therapeutics, Tizona Therapeutics, and Tusk Therapeutics.

“In addition to welcoming new partners, we take tremendous pride in generating longer-term relationships with our existing partners,” commented Guy Van Meter, Vice President of Business Development at Adimab. “Most of Adimab’s existing partners have sought to expand their relationships beyond the initial terms of the engagement; recently expanded partnerships include those with Five Prime, Innovent Biologics, Acceleron, Potenza, Jounce Therapeutics, Surface Oncology, and Alector.”

“Adimab’s discovery and protein engineering capabilities surpass simple affinity maturation, and can be utilized to enhance multiple attributes of an antibody or bi-specific to ensure the best possible product candidates for a given therapeutic program,” added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “We are very pleased to see so many of our existing collaborations expanding into broader partnerships. The more successful our projects are, the more our partners want to do – it’s as simple as that.”

Adimab also announced that it has recently achieved technical milestones with several partners, including Merck, Acceleron Pharmaceuticals, Kite Pharma, Surface Oncology, and Potenza Therapeutics. Merck has recently exercised a commercial license under one of its earlier agreements and Arsanis Biosciences has initiated a Phase I clinical study in healthy volunteers.

“Adimab’s protein engineering capabilities generated therapeutic leads for our ASN100 program that no other technology could have produced – including a very unique antibody that is highly effective against five separate toxins of Staphylococcus aureus with very low sequence homology,” said Eszter Nagy, Chief Scientific Officer and co-founder of Arsanis. “We are very happy to have a partnership with Adimab and are pleased that our first program has already reached the clinic.”

Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many smaller companies, such as Merrimack Pharmaceuticals, Mersana, Five Prime and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Novo Nordisk, Biogen, and GSK for internal use.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.